Ferroptosis: The Entanglement Between Traditional Drugs and Nanodrugs in Tumor Therapy

Kexuan Liu,Lei Huang,Shuangyan Qi,Shuchen Liu,Wangni Xie,Liuyi Du,Jing Cui,Xu Zhang,Boya Zhang,Lijun Liu,Daowei Li,Hongchen Sun

DOI: https://doi.org/10.1002/adhm.202203085

IF: 10

2023-01-21

Advanced Healthcare Materials

Abstract:Ferroptosis is a non‐apoptotic programmed cell death caused by accumulation of lipid peroxide. System Xc‐ /GPX4 axis and iron axis are two main pathways regulating ferroptosis. Simultaneously, multiple pathways are also involved in ferroptosis regulation. Ferroptosis is an intense area of current study. With the improvement of the regulatory mechanisms that underlie ferroptosis, a variety of drugs associated with ferroptosis have been discovered and developed for cancer therapy. Among them, traditional drugs developed initially. Small molecule compounds that regulate ferroptosis signaling pathway and iron complexes that promote the Fenton reaction have become important drugs for inducing ferroptosis. In recent years, the emerging development of nanotechnology has promoted the research of ferroptosis nanodrugs. Iron‐based nanomaterials have been extensively tested as ferroptosis‐inducing agents. Furthermore, nanoscale drug delivery systems offer a suitable scaffold for traditional drug therapies. Traditional drugs and nanodrugs are complementary, each with their own strengths and limitations. This review describes the latest studies on the regulation of ferroptosis in tumor cells and focuses on the entanglement between traditional drugs and nanodrugs (Figure 1). To conclude, the challenges and perspectives in this field are put forward. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials